Twist Bioscience Corp (TWST): Shareholders' Equity
$472.96M
As of 2025-09-30
$445.74M
As of 2026-06-30
-15.7%
3-year compound annual growth
+7.1%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | $472.96M | +0.1% | 2025-11-17, Balance as of period end |
| 2024-09-30 | $472.69M | -24.2% | 2025-11-17, Balance as of period end |
| 2023-09-30 | $623.43M | -21.0% | 2025-11-17, Balance as of period end |
| 2022-09-30 | $789.38M | +35.9% | 2024-11-18, Balance as of period end |
| 2021-09-30 | $580.82M | +72.7% | 2023-11-21, Balance as of period end |
| 2020-09-30 | $336.26M | +121.1% | 2023-06-05, Balance as of period end |
| 2019-09-30 | $152.08M | n/m | 2021-11-23, Balance as of period end |
| 2018-09-30 | -$201.42M | n/m | 2020-11-27, Balance as of period end |
| 2017-09-30 | -$133.36M | n/a | 2019-12-13, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | 2025-09-30 | $472.96M | +0.1% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $1.22B | +28.9% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $381.03M | +5.6% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $343.43M | +53.0% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $477.32M | +36.8% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $218.79M | +7.9% |
| Vericel Corp (VCEL) | 2025-12-31 | $354.64M | +21.5% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $698.58M | -1.7% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $87.80M | +49.0% |
Compare TWST, KRYS, IMCR, TARS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗